Best Treatments for Headaches That Won't Go Away in 2026

Headaches that last for weeks or months, resist over-the-counter painkillers, and disrupt daily life affect more people than most realize. Roughly 15% of US adults report migraine or severe headache in any given three-month period, and for a subset of those, the pain becomes chronic, defined as 15 or more headache days per month for at least three months.

Treatment options have expanded significantly in recent years. From brain-based behavioral therapies to newer medications that target the biology of migraine itself, adults with persistent headaches now have more evidence-backed choices than at any point in modern medicine. Here are eight treatments with the strongest current evidence.

Key Takeaways

• Central sensitization, where the brain amplifies pain signals beyond the original trigger, is present in up to 90% of adults with chronic migraine.
• Brain-first behavioral approaches (CBT, ACT, somatic tracking) carry Grade A evidence for migraine prevention and can reduce headache frequency without medication side effects.
• CGRP-targeting medications, approved since 2018, reduce monthly migraine days by half in roughly 28-61% of adults with chronic migraine.
• The AAN and AHS published updated migraine prevention guidelines in August 2026, expanding recommended options for adults with four or more migraine days per month.
• Combining behavioral and medical treatments often produces the strongest outcomes for people with persistent headaches.

1. Brain-First Behavioral Therapy

When headaches persist for months or years, the nervous system itself can change. Research shows that central sensitization, a state in which the brain amplifies pain signals even without ongoing tissue damage, is present in the vast majority of adults with chronic migraine. The pain alarm gets stuck.

Brain-first behavioral therapy targets this mechanism directly. Rather than masking symptoms with medication, it retrains the neural pathways that keep pain signals firing.

What the evidence shows

Behavioral therapies carry Grade A evidence for migraine prevention from the US Headache Consortium, meaning they have the highest level of support from randomized controlled trials. Specific approaches with evidence for headache include:

• Cognitive behavioral therapy (CBT): A meta-analysis found that CBT reduces headache frequency in adults with chronic migraine, with treatment feasibility rates exceeding 80%.
• Acceptance and commitment therapy (ACT): A 2024 meta-analysis of 21 RCTs found ACT produces medium pain-related effects in adults with chronic pain conditions.
• Mindfulness-based stress reduction (MBSR): In a randomized trial, enhanced MBSR achieved a 52% response rate (50% or greater reduction in headache days), compared with 23% for standard stress management alone.
• Somatic tracking and pain reprocessing: These techniques teach patients to observe pain sensations with curiosity rather than fear, interrupting the fear-pain cycle that sustains central sensitization.

Who it may help most

Brain-first therapy is particularly worth considering for adults whose headaches have persisted despite medication, those with headaches that spread to new areas over time, and people who notice that stress, emotions, or sleep disruptions reliably affect their pain. It works alongside medical treatment, not as a replacement.

2. CGRP-Targeting Medications

Calcitonin gene-related peptide (CGRP) plays a central role in migraine biology. Since 2018, the FDA has approved several medications that either block CGRP or its receptor:

• Monoclonal antibodies (injectable): erenumab, fremanezumab, galcanezumab, eptinezumab
• Gepants (oral): atogepant, rimegepant, ubrogepant, zavegepant

What the evidence shows

Anti-CGRP monoclonal antibodies halve monthly migraine days in approximately 28-61% of adults with chronic migraine. In clinical trials, about 41% of patients converted from chronic to episodic migraine. The oral gepants show comparable effectiveness and can serve dual roles: rimegepant and atogepant are approved for both acute treatment and prevention.

The AAN/AHS 2026 guideline lists CGRP-targeted therapies among the most tolerable preventive options, alongside established agents like propranolol and topiramate.

Who it may help most

Adults with four or more migraine days per month who have not responded adequately to older preventives, or who experienced intolerable side effects from topiramate or beta-blockers. CGRP therapies have a favorable side-effect profile, though cost and insurance coverage vary by plan.

3. OnabotulinumtoxinA (Botox)

OnabotulinumtoxinA has been FDA-approved specifically for chronic migraine since 2010. Treatment involves 31 injections across the head and neck every 12 weeks.

What the evidence shows

A 2024 multicenter retrospective study across 19 headache clinics followed 489 adults receiving onabotulinumtoxinA for more than five years. Key outcomes:

• 59% of patients were classified as responders
• Average reduction of 9.4 monthly migraine days (from 15.7 to 6.3)
• Average reduction of 14.9 monthly headache days (from 24.7 to 9.8)
• No serious adverse events after more than five years of continuous treatment

Common side effects include neck pain (17.5%) and temporary eyelid drooping (8.5%).

The AAN/AHS 2026 guideline specifically includes onabotulinumtoxinA as an evidence-based option for chronic migraine prevention.

Who it may help most

Adults with chronic migraine (15 or more headache days per month) who have tried at least two oral preventives without adequate relief. OnabotulinumtoxinA is particularly well-studied for this population.

4. Biofeedback Training

Biofeedback uses sensors to give patients real-time feedback on physiological processes like muscle tension, skin temperature, and heart rate variability. Over multiple sessions, patients learn to regulate these responses voluntarily, reducing the physiological triggers of headache.

What the evidence shows

A 2025 systematic review and meta-analysis of randomized controlled trials from 2000 to 2024 confirmed that biofeedback reduces headache frequency and severity compared with no treatment. The review also found that combining biofeedback with medication produced synergistic benefits beyond either approach alone.

When compared head-to-head with CBT or pharmacotherapy, biofeedback showed no significant advantage, suggesting it is one of several effective behavioral options rather than a standout performer.

Who it may help most

Adults who prefer a concrete, data-driven approach to self-regulation, those who want to reduce medication use, and people whose headaches are strongly tied to muscle tension or stress arousal. Biofeedback carries essentially zero risk of side effects.

5. Neuromodulation Devices

Several FDA-cleared devices deliver electrical or magnetic stimulation to nerves involved in headache, offering drug-free treatment options:

• Cefaly: external trigeminal nerve stimulation, cleared for both prevention and acute treatment, available over the counter since 2020, and the most-prescribed neuromodulation device in the Veterans Health Administration system as of 2025
• gammaCore Sapphire: non-invasive vagus nerve stimulation for acute and preventive treatment of migraine and cluster headache
• SAVI Dual (sTMS): single-pulse transcranial magnetic stimulation for acute and preventive migraine treatment
• Nerivio: remote electrical neuromodulation, FDA-cleared for ages 8 and older as of November 2024

What the evidence shows

These devices have demonstrated efficacy in controlled trials, though effect sizes tend to be modest compared with pharmacological preventives. Their primary advantage is a near-absence of systemic side effects, making them suitable as add-on therapy or standalone options for patients who cannot tolerate medications.

Who it may help most

Adults who cannot tolerate preventive medications, those with medication overuse headache who need drug-free alternatives, and people who prefer non-pharmaceutical options. Some devices are also cleared for use in children and adolescents.

6. Acupuncture

Acupuncture involves the insertion of thin needles at specific points on the body. It has a long history in headache treatment and increasingly rigorous evidence to support it.

What the evidence shows

A 2025 Cochrane review on episodic migraine prevention found that acupuncture is at least as effective as standard prophylactic medications, with fewer adverse effects. In controlled trials, patients receiving acupuncture had higher response rates and fewer headache days compared with no preventive treatment.

For chronic migraine specifically, acupuncture may be a reasonable choice when pharmacological prevention is not suitable or when patients prefer non-drug approaches.

Who it may help most

Adults who want a non-pharmacological preventive option, those with medication sensitivities, and patients already engaged in integrative care. Acupuncture has an excellent safety profile when performed by a licensed practitioner.

7. Preventive Medications (Established Options)

Before CGRP therapies, several medication classes formed the backbone of migraine prevention. The AAN/AHS 2026 guideline, based on a systematic review of evidence through June 2024, still recommends these as evidence-based options:

• Beta-blockers: propranolol, metoprolol
• Antiepileptics: topiramate, valproate
• Antidepressants: amitriptyline, venlafaxine
• Angiotensin receptor blockers: candesartan

What the evidence shows

These medications have decades of use and extensive long-term safety data. The 2026 guideline notes that some patients may prefer these longer-established options precisely because of their known safety profiles.

Common trade-offs include weight change (topiramate tends toward loss, valproate toward gain), fatigue (beta-blockers), and cognitive effects (topiramate). The guideline emphasizes shared decision-making: efficacy, tolerability, cost, comorbidities, and patient preference should all factor into the choice.

Who it may help most

Adults with coexisting conditions that a preventive might address simultaneously. For instance, propranolol can help with both migraine and anxiety, while amitriptyline may benefit patients with migraine and comorbid insomnia or depression.

8. Lifestyle and Trigger Management

Consistent daily habits form the foundation of headache management. While they rarely eliminate chronic headaches on their own, they meaningfully reduce attack frequency and improve the effectiveness of other treatments.

What the evidence shows

• Exercise: A systematic review of trials from 2020 to 2024 found that aerobic exercise and yoga reduce migraine frequency, with aerobic exercise earning a Grade B recommendation for migraine prevention. Regular exercise also reduces stress and sleep disturbances, two of the strongest migraine triggers.
• Sleep consistency: Irregular sleep is among the most commonly reported migraine triggers. CBT for insomnia in migraine patients has shown reductions in headache frequency alongside sleep improvements.
• Stress management: Since stress is implicated in a large percentage of migraine attacks, structured techniques like progressive muscle relaxation, guided imagery, and pain journaling can reduce the frequency of stress-triggered episodes.
• Hydration and regular meals: Skipped meals and dehydration are among the most easily modifiable triggers for many adults with migraine.

Who it may help most

Everyone with persistent headaches. Lifestyle modifications complement every other treatment on this list and carry no side effects. They are also the only approach that addresses multiple headache triggers at once.

How Lin Health Helps with Headaches That Won't Go Away

Many people with chronic headaches cycle through medications, injections, and specialist visits without lasting relief. When headaches persist despite treatment, the problem may not be in the head or neck tissues themselves. It may be in how the brain's pain-processing system has learned to keep the alarm firing.

Lin Health's approach is based on findings from neuroplastic pain research. The program uses evidence-based behavioral techniques, including CBT, ACT, somatic tracking, and emotional awareness exercises, to help retrain the neural pathways that sustain chronic migraine and other persistent headache conditions. Each patient works one-on-one with a trained recovery coach through weekly live sessions, between-session chat support, and an app with guided learning and practice tools.

What sets this apart from general talk therapy:

• Specialized in persistent physical symptoms, including chronic migraine and headache, not general mental health
• Covered by most major insurance plans in Colorado, Texas, Florida, California, and New York
• Short wait times, often with a same-day callback after signup
• Coach-led, not self-paced, because research suggests coached programs produce stronger outcomes than app-only or book-only approaches

For more on how these techniques apply to chronic headache, see Lin Health's resources on imaginal exposure for migraines and chronic migraine prevention.

Lin Health offers behavioral and lifestyle support for chronic headaches, delivered by trained recovery coaches and covered by most insurance plans in CO, TX, FL, CA, and NY. Wait times are short, often a same-day call. Check your eligibility.

FAQ

What qualifies as a headache that won't go away?

Headaches lasting more than 15 days per month for three months or longer meet the clinical definition of chronic headache. This includes chronic migraine, chronic tension-type headache, new daily persistent headache, and medication overuse headache. A neurologist or headache specialist can help determine the specific type.

Can behavioral therapy really help with physical headaches?

Yes. Behavioral therapies like CBT and biofeedback carry Grade A evidence for migraine prevention from the US Headache Consortium. They work by changing how the brain processes pain signals, stress responses, and fear-pain cycles, rather than masking symptoms with medication.

What are CGRP medications, and who should consider them?

CGRP-targeting therapies are newer medications (available since 2018) that block a protein involved in migraine attacks. The AAN/AHS 2026 guideline recommends them for adults with four or more migraine days per month. They come as monthly injections or daily oral pills.

Is medication overuse making my headaches worse?

Possibly. Medication overuse headache affects 1-2% of the general population and develops when acute headache medications are used more than 10-15 days per month for three or more months. Withdrawal with preventive therapy support can lead to meaningful improvement for most patients.

Should I try multiple treatments at the same time?

Many headache specialists recommend combining approaches. Pairing a preventive medication with behavioral treatment (such as CBT or biofeedback) and lifestyle modifications often produces better outcomes than any single treatment alone. Talk with your clinician about which combination fits your situation.

Does insurance cover these treatments?

Coverage varies by treatment and plan. CGRP medications, Botox for chronic migraine, and behavioral therapy are covered by many US insurers. Lin Health's behavioral program is covered by most major insurance plans in Colorado, Texas, Florida, California, and New York, with most patients paying nothing out of pocket.

This article is for informational purposes and is not medical advice. Consult a qualified healthcare provider before starting, stopping, or changing any headache treatment plan.